M cells prefer archaeosomes: an in vitro/in vivo snapshot upon oral gavage in rats
- PMID: 21291382
- DOI: 10.2174/156720111795256138
M cells prefer archaeosomes: an in vitro/in vivo snapshot upon oral gavage in rats
Abstract
The archaeolipids (lipids extracted from archaebacterias) are non saponificable molecules that form self sealed mono or bilayers (archaeosomes-ARC). Different to liposomes with bilayers made of conventional glycerophospholipids, the bilayer of ARC posses a higher structural resistance to physico chemical and enzymatic degradation and surface hydrophobicity. In this work we have compared the binding capacity of ARC exclusively made of archaeols containing a minor fraction of sulphoglycophospholipids, with that of liposomes in gel phase on M-like cells in vitro. The biodistribution of the radiopharmaceutical (99m)Tc-DTPA loaded in ARC vs that of liposomes upon oral administration to Wistar rats was also determined. The fluorescence of M-like cells upon 1 and 2h incubation with ARC loaded with the hydrophobic dye Rhodamine-PE (Rh-PE) and the hydrophilic dye pyranine (HPTS) dissolved in the aqueous space, was 4 folds higher than upon incubation with equally labeled liposomes. Besides, 15% of Rh-PE and 13 % of HPTS from ARC and not from liposomes, were found in the bottom wells, a place that is equivalent to the basolateral pocket from M cells. This fact suggested the occurrence of transcytosis of ARC. Finally, 4 h upon oral administration, ARC were responsible for the 22.3 % (3.5 folds higher than liposomes) shuttling of (99m)Tc-DTPA to the blood circulation. This important amount of radioactive marker in blood could be a consequence of an extensive uptake of ARC by M cells in vivo, probably favored by their surface hydrophobicity. Taken together, these results suggested that ARC, proven their adjuvant capacity when administered by parenteral route and high biocompatibility, could be a suitable new type of nanoparticulate material that could be used as adjuvants by the oral route.
Similar articles
-
Archaeosomes: an excellent carrier for drug and cell delivery.Drug Deliv. 2016 Sep;23(7):2497-2512. doi: 10.3109/10717544.2015.1019653. Epub 2015 Mar 17. Drug Deliv. 2016. PMID: 25777339
-
Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems.Crit Rev Biotechnol. 1999;19(4):317-57. doi: 10.1080/0738-859991229170. Crit Rev Biotechnol. 1999. PMID: 10723627 Review.
-
The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo.J Immunol. 2001 Feb 1;166(3):1885-93. doi: 10.4049/jimmunol.166.3.1885. J Immunol. 2001. PMID: 11160236
-
Folate-PEG-CKK(2)-DTPA, A Potential Carrier for Lymph-Metastasized Tumor Targeting.Pharm Res. 2010 May;27(5):933-42. doi: 10.1007/s11095-010-0100-3. Epub 2010 Mar 11. Pharm Res. 2010. PMID: 20221899
-
Archaeosome immunostimulatory vaccine delivery system.Curr Drug Deliv. 2005 Oct;2(4):407-21. doi: 10.2174/156720105774370285. Curr Drug Deliv. 2005. PMID: 16305444 Review.
Cited by
-
Archaeosomes for Oral Drug Delivery: From Continuous Microfluidics Production to Powdered Formulations.Pharmaceutics. 2024 May 23;16(6):694. doi: 10.3390/pharmaceutics16060694. Pharmaceutics. 2024. PMID: 38931818 Free PMC article.
-
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.J Drug Deliv. 2012;2012:750891. doi: 10.1155/2012/750891. Epub 2011 Nov 24. J Drug Deliv. 2012. PMID: 22175030 Free PMC article.
-
Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery.ISRN Pharm. 2012;2012:474830. doi: 10.5402/2012/474830. Epub 2012 Jul 19. ISRN Pharm. 2012. PMID: 22888455 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources